IRB #

IRB00007895

Title

S1005, “A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer”

Principal Investigator

Gina Vaccaro

Study Purpose

The primary aim of this study is to find out what effects,good and/or bad, the study drug MK-2206 has on subjects with gastric or gastroesophageal (GE) junction cancer.

Medical Condition(s)

Stomach

Eligibility Criteria

* Cancer of Stomach or between Stomach and Esophagus (Gastroesophageal Junction)
* Must have prior chemotherapy which led to progression, or a recurrence.
* No chemotherapy or radiotherapy within 3 weeks prior to registration

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Participants will continue to take the study drug until their disease gets worse or the side effects become too bad.

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

SWOG

Recruitment End

Compensation Provided

No